Raptor Pharmaceutical Corp. is a biopharmaceutical company. The company is engaged in the development of therapeutics for rare diseases. The company’s first FDA-approved product is designed to manage nephropathic cystinosis. The company’s pipeline includes developmental programs in a variety of therapeutic areas.